Literature DB >> 34179821

Recommendations on eliminating racial disparities in multiple myeloma therapies: a step toward achieving equity in healthcare.

Nicole Gormley1, Lola Fashoyin-Aje1, Trevan Locke2, Joseph M Unger3, Richard F Little4, Ajay Nooka5, Khalid Mezzi6, Mihaela Popa-McKiver7, Rachel Kobos8, Yelak Biru9, Tiffany H Williams10, Kenneth C Anderson11.   

Abstract

African Americans are at higher risk of multiple myeloma (MM) yet underrepresented in clinical trials and reap less benefits from novel therapies of the disease. To improve representation of African Americans in MM clinical trials, researchers, providers, patients, industry partners and regulators at the FDA-AACR workshop developed recommendations to all stakeholders. The outlined principles offer a roadmap to addressing disparities broadly in clinical trials.

Entities:  

Mesh：

Year:  2021        PMID： 34179821      PMCID： PMC8224821          DOI： 10.1158/2643-3230.BCD-20-0123

Source DB:  PubMed          Journal:  Blood Cancer Discov        ISSN： 2643-3230


  9 in total

1.  The New FDA Real-World Evidence Program to Support Development of Drugs and Biologics.

Authors:  David C Klonoff
Journal:  J Diabetes Sci Technol       Date:  2019-03-12

2.  Cancer statistics for African Americans, 2019.

Authors:  Carol E DeSantis; Kimberly D Miller; Ann Goding Sauer; Ahmedin Jemal; Rebecca L Siegel
Journal:  CA Cancer J Clin       Date:  2019-02-14       Impact factor: 508.702

3.  Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis.

Authors:  Sikander Ailawadhi; Kejal Parikh; Safiya Abouzaid; Zhou Zhou; Wenxi Tang; Zoe Clancy; Claudia Cheung; Zheng-Yi Zhou; Jipan Xie
Journal:  Blood Adv       Date:  2019-10-22

Review 4.  Closing the Rural Cancer Care Gap: Three Institutional Approaches.

Authors:  Laura A Levit; Leslie Byatt; Alan P Lyss; Electra D Paskett; Kathryn Levit; Kelsey Kirkwood; Caroline Schenkel; Richard L Schilsky
Journal:  JCO Oncol Pract       Date:  2020-06-23

5.  Racial disparities in incidence and outcome in multiple myeloma: a population-based study.

Authors:  Adam J Waxman; Pamela J Mink; Susan S Devesa; William F Anderson; Brendan M Weiss; Sigurdur Y Kristinsson; Katherine A McGlynn; Ola Landgren
Journal:  Blood       Date:  2010-09-07       Impact factor: 22.113

6.  Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018.

Authors:  Jonathan M Loree; Seerat Anand; Arvind Dasari; Joseph M Unger; Anirudh Gothwal; Lee M Ellis; Gauri Varadhachary; Scott Kopetz; Michael J Overman; Kanwal Raghav
Journal:  JAMA Oncol       Date:  2019-10-10       Impact factor: 31.777

7.  Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients.

Authors:  S K Kumar; A Dispenzieri; M Q Lacy; M A Gertz; F K Buadi; S Pandey; P Kapoor; D Dingli; S R Hayman; N Leung; J Lust; A McCurdy; S J Russell; S R Zeldenrust; R A Kyle; S V Rajkumar
Journal:  Leukemia       Date:  2013-10-25       Impact factor: 11.528

8.  Representativeness of Black Patients in Cancer Clinical Trials Sponsored by the National Cancer Institute Compared With Pharmaceutical Companies.

Authors:  Joseph M Unger; Dawn L Hershman; Raymond U Osarogiagbon; Anirudh Gothwal; Seerat Anand; Arvind Dasari; Michael Overman; Jonathan M Loree; Kanwal Raghav
Journal:  JNCI Cancer Spectr       Date:  2020-04-24

9.  Differences in genomic abnormalities among African individuals with monoclonal gammopathies using calculated ancestry.

Authors:  Linda B Baughn; Kathryn Pearce; Dirk Larson; Mei-Yin Polley; Eran Elhaik; Michael Baird; Colin Colby; Joanne Benson; Zhuo Li; Yan Asmann; Terry Therneau; James R Cerhan; Celine M Vachon; A Keith Stewart; P Leif Bergsagel; Angela Dispenzieri; Shaji Kumar; S Vincent Rajkumar
Journal:  Blood Cancer J       Date:  2018-10-10       Impact factor: 11.037
  9 in total
  6 in total

Review 1.  Diversity upon diversity: linking DNA double-strand break repair to blood cancer health disparities.

Authors:  Jason N Sterrenberg; Melissa L Folkerts; Valeria Rangel; Sarah Eugenie Lee; Nicholas R Pannunzio
Journal:  Trends Cancer       Date:  2022-01-31

2.  Blood Cancer Discovery Turns One.

Authors:  Riccardo Dalla-Favera; Kenneth C Anderson
Journal:  Blood Cancer Discov       Date:  2021-07-01

3.  The FDA Oncology Center of Excellence Scientific Collaborative: Charting a Course for Applied Regulatory Science Research in Oncology.

Authors:  Julie A Schneider; Yutao Gong; Kirsten B Goldberg; Paul G Kluetz; Marc R Theoret; Laleh Amiri-Kordestani; Julia A Beaver; Lola Fashoyin-Aje; Nicole J Gormley; Adnan A Jaigirdar; Steven J Lemery; Pallavi S Mishra-Kalyani; Gregory H Reaman; Donna R Rivera; Wendy S Rubinstein; Harpreet Singh; Rajeshwari Sridhara; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2021-10-01       Impact factor: 12.531

4.  Racial and Ethnic Disparities Among Participants in Precision Oncology Clinical Studies.

Authors:  Christopher M Aldrighetti; Andrzej Niemierko; Eliezer Van Allen; Henning Willers; Sophia C Kamran
Journal:  JAMA Netw Open       Date:  2021-11-01

5.  Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN.

Authors:  Ajay K Nooka; Jonathan L Kaufman; Cesar Rodriguez; Andrzej Jakubowiak; Yvonne Efebera; Brandi Reeves; Tanya Wildes; Sarah A Holstein; Larry D Anderson; Ashraf Badros; Leyla Shune; Ajai Chari; Huiling Pei; Annelore Cortoos; Sharmila Patel; J Blake Bartlett; Jessica Vermeulen; Thomas S Lin; Paul G Richardson; Peter Voorhees
Journal:  Blood Cancer J       Date:  2022-04-13       Impact factor: 9.812

6.  Global Myeloma Trial Participation and Drug Access in the Era of Novel Therapies.

Authors:  Raleigh Ayoolu Fatoki; Kelly Koehn; Amar Kelkar; Samer Al Hadidi; Nikita Mehra; Hira Mian; Ola Landgren; Dickran Kazandjian; James Hoffman; Douglas W Sborov; Ghulam Rehman Mohyuddin
Journal:  JCO Glob Oncol       Date:  2022-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.